Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

University of Guelph

$78,698.00

Defining mechanisms of plant-pathogen interactions by quantitative proteomics for improved strategies in molecular farming

FY 2020-21

Summary
Transient expression of recombinant proteins in plants is increasingly being used as a production platform for therapeutic proteins such as monoclonal antibodies, enzymes, and vaccines. Benefits of this system include a reduced cost of drug development, rapid delivery of new products to the market, and an ability to provide safe and efficacious medicines for diseases such as arthritis and cancer. PlantForm Corporation is a Canadian biotechnology company that has developed such a system to produce biosimilar versions of therapeutics (e.g. Humira® and Herceptin®), as well as innovative products against pathogens (e.g. HIV and Ebola virus). The basis of PlantForm's technology, known as vivoXPRESS®, is to use a common plant pathogen (Agrobacterium tumefaciens) to deliver genes encoding for a specific protein product to plant cells (Nicotiana benthamiana). This approach provides a technology in which the plant becomes a factory for manufacturing of the desired product. A recent NSERC Engage grant (2017) with Dr. E. Allen-Vercoe (collaborator on this NSERC CRD project; University of Guelph) resulted in scalable methods using microbial fermentation for production of Agrobacterium cultures. However, despite these advances, a comprehensive understanding of the impact of Agrobacterium infiltration from both the pathogen and host perspectives, has not been performed. Here, the proposed research project builds directly upon the success of the NSERC Engage grant to profile differences in protein and metabolite abundance in A. tumefaciens and N. benthamiana following agroinfiltration to determine steps in the production process, which can be tailored for optimal target protein production. The results from this research project will provide valuable insight into patterns of regulation at the cellular level in the pathogen and host during infection and characterize mechanisms of protein delivery by Agrobacterium. We anticipate our results to translate into substantial increases in protein production and significant cost savings for new product development for PlantForm. Ultimately, we aim to reduce barriers for the production of new, safe, and effective therapeutics in Canada.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
539389-2019
Name nom
Geddes-McAlister, Jennifer
Department département
Molecular and Cellular Biology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2019
Award amount
78698
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
103
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Plant production and plant primary products
Area of application fr
Production végétale et produits végétaux primaires
Research subject code
1200
Research subject group en
Agricultural engineering
Research subject group fr
Génie rural
Research subject en
Agricultural engineering
Research subject fr
Génie rural
Installment
inst:2 - 2
Partie
1
Nb partie
2
Application title
Defining mechanisms of plant-pathogen interactions by quantitative proteomics for improved strategies in molecular farming
Keyword
NSERC
Application summary
Transient expression of recombinant proteins in plants is increasingly being used as a production platform for therapeutic proteins such as monoclonal antibodies, enzymes, and vaccines. Benefits of this system include a reduced cost of drug development, rapid delivery of new products to the market, and an ability to provide safe and efficacious medicines for diseases such as arthritis and cancer. PlantForm Corporation is a Canadian biotechnology company that has developed such a system to produce biosimilar versions of therapeutics (e.g. Humira® and Herceptin®), as well as innovative products against pathogens (e.g. HIV and Ebola virus). The basis of PlantForm's technology, known as vivoXPRESS®, is to use a common plant pathogen (Agrobacterium tumefaciens) to deliver genes encoding for a specific protein product to plant cells (Nicotiana benthamiana). This approach provides a technology in which the plant becomes a factory for manufacturing of the desired product. A recent NSERC Engage grant (2017) with Dr. E. Allen-Vercoe (collaborator on this NSERC CRD project; University of Guelph) resulted in scalable methods using microbial fermentation for production of Agrobacterium cultures. However, despite these advances, a comprehensive understanding of the impact of Agrobacterium infiltration from both the pathogen and host perspectives, has not been performed. Here, the proposed research project builds directly upon the success of the NSERC Engage grant to profile differences in protein and metabolite abundance in A. tumefaciens and N. benthamiana following agroinfiltration to determine steps in the production process, which can be tailored for optimal target protein production. The results from this research project will provide valuable insight into patterns of regulation at the cellular level in the pathogen and host during infection and characterize mechanisms of protein delivery by Agrobacterium. We anticipate our results to translate into substantial increases in protein production and significant cost savings for new product development for PlantForm. Ultimately, we aim to reduce barriers for the production of new, safe, and effective therapeutics in Canada.